Pinterest • The world’s catalogue of ideas

Dr. Reddy’s Laboratories and XenoPort Enter Into a U.S. Licensing Agreement for XP23829

Dr. Reddy's Laboratories (BSE: NSE: DRREDDY, NYSE: RDY) and XenoPort, Inc. (NASDAQ: XNPT) announced today that they have entered into a licens

The 30-share BSE Sensex was up 70.33 points at 26713.57 and the 50-share NSE Nifty rose 23.15 points to 8215.40 while the BSE Midcap and Smallcap indices gained 0.6 percent each. Infosys was down 0.61 percent at USD 14.74 and Wipro shed 1.55 percent at USD 9.53.ICICI Bank was up 0.13 percent at USD 7.50 and HDFC Bank declined 2.47 percent at USD 59.18.Tata Motors rose 3.29 percent at USD 35.52 and Dr Reddy’s Laboratories added 0.35 percent at USD 45.44. For More Info visit…

Dr Reddy's April-June quarter earnings have surpassed street estimates with net profit rising 14 percent to Rs 626 crore from Rs 550.4 crore in corresponding quarter last fiscal. Total income, - See more at:

heart 1

Shares of Dr Reddy's Laboratories added 1.3 percent intraday Monday after the drug maker launched HAiROOTZ. - See more at:

heart 1

Indore - इंदौर

Dr. Reddy`s Lab to present at J.P. Morgan Healthcare Conference -10 Jan,2017 :->Dr. Reddy’s Laboratories Ltd. Has said that the company will present at the J.P. Morgan 35th Annual Healthcare Conference on Tuesday, January 10th, 2017, in San Francisco. The presentation is scheduled to begin at 2:30 p.m. PST [4:00 a.m. IST on January 11th, 2017]. Presentation material will be available on the Company’s website

Dr Reddy's Laboratories Ltd has announced that it has launched Nise D Spray in Indian Market. Dr Reddys Laboratories Ltd is currently trading at Rs. 4261.2, down by Rs. 8.3 or 0.19% from its previous closing of Rs. 4269.5 on the BSE. - See more at:

Dr Reddy's Laboratories, Japan's Eisai ink licensing pact for anticancer agent | ET HealthWorld

Dr. Reddy's buy back offer would open on 18th April, 2016. Dr Reddy laboratories planning for Rs 1,569 Crores buy back offer. Should you participate in this offer?